Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Emisphere -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (154)	5/22/2001 4:56:07 PM
From: Ian@SI	Respond to of 272

Emisphere Technologies, Inc. Presentation at UBS Warburg Specialty Pharmaceutical Conference To Be Telecast TARRYTOWN, N.Y., May 22, 2001 /PRNewswire via COMTEX/ -- Emisphere Technologies, Inc., Chairman and Chief Executive Officer, Michael M. Goldberg, M.D., will present to the investment community for the UBS Warburg Global Specialty Pharmaceutical Conference in New York, tomorrow, May 23, 2001 at 9:00 a.m. Eastern Time. Interested investors can access the audio portion of the presentation by dialing 888-515-2781 within the United States or 719-457-2605 outside the U.S. A replay of this presentation will be available by the end of the presentation day, and can be accessed by dialing 800-759-8603 within the U.S. or 402-220-8537 outside the U.S. The replay will be archived for 14 days. Note, the slides from the presentation will also be posted and accessible at corporate-ir.net. Emisphere Technologies, Inc., is a biopharmaceutical company pioneering the oral delivery of otherwise injectable drugs. By applying its unique carrier technology, Emisphere has taken a leadership position in solving the oral delivery of proteins, peptides and other macromolecules produced by both pharmaceutical and biotechnology companies. Four Emisphere formulations have been advanced into human clinical trials being conducted by Emisphere and its partners. Emisphere develops pharmaceutical products for its own portfolio and has several strategic alliances and ongoing feasibility studies with many of the world's leading pharmaceutical and biotechnology companies, including Novartis Pharma AG, Eli Lilly and Company, Regeneron Pharmaceuticals, Inc. and Cubist Pharmaceuticals, Inc.

To: Ian@SI who wrote (154)	5/14/2002 9:24:18 AM
From: tuck	Read Replies (2) \| Respond to of 272

>>TARRYTOWN, N.Y., May 14 /PRNewswire-FirstCall/ -- Emisphere Technologies, Inc. (Nasdaq: EMIS - News), today announced initial results from its Phase III study with an oral heparin formulation for the prevention of deep vein thrombosis (DVT, or blood clots) in total hip replacement surgery patients. The results did not demonstrate the superiority of oral heparin, when dosed in a 30-day treatment regimen, compared to Aventis' Lovenox® (enoxaparin) administered by injection in a 10-day dosing regimen in preventing DVTs. "The rigorous study design of PROTECT sought at least an absolute 10% reduction in DVT events, to claim clinical superiority to the FDA," said Russell Hull, M.D., Director of the Thrombosis Research Unit, University of Calgary, Canada, PROTECT Steering Committee Chairman and the study's lead investigator for its North American study sites. "Data from the recently completed PROTECT study suggests that there was lower efficacy due to limitations related to the dosage form and that an improved formulation would result in higher patient compliance. While we are disappointed that we missed the anticipated primary endpoint, we are encouraged by the fact that orally administered heparin is clearly active and therefore a major advance in oral macromolecule delivery." "We are disappointed that we did not meet the primary efficacy endpoint of the PROTECT Trial. Although we did not prove superiority of oral heparin compared to injected Lovenox, it was clear that with our carrier technology we were able to demonstrate the effectiveness of oral heparin in preventing deep vein thrombosis," said Michael M. Goldberg, M.D., Emisphere's Chairman and Chief Executive Officer. "While we acknowledge our disappointment with the results of the PROTECT study, we remain encouraged by the potential of our broadly applicable technology platform." "Most importantly, this study reinforces the Emisphere technology for the oral delivery of macromolecules," stated Alan W. Dunton, M.D., President and Chief Operating Officer. "We will redefine our oral heparin program in the context of the performance of the product in the PROTECT study and remain committed to our other products currently in clinical development." About PROTECT The PROTECT Trial enrolled 2,288 patients to evaluate the safety and efficacy of oral heparin formulation using Emisphere's proprietary oral drug delivery technology for the prevention of DVT in total hip replacement surgery patients (a surgical patient population that historically has had the highest rate of these events). The goal of the PROTECT Trial was to demonstrate the superior efficacy and comparable safety of Emisphere's oral heparin when dosed postoperatively for a 30-day regimen, as compared to injectable enoxaparin, when dosed postoperatively for a 10-day regimen. (A 10-day regimen of injectable Lovenox is a standard of practice in the prevention of DVT, as determined by the American College of Chest Physicians' Sixth Consensus Conference.) Study Design The endpoint of PROTECT (Prophylaxis with Oral Heparin/Emisphere® SNAC against ThromboEmbolic Complications following Total Hip Replacement Surgery was DVT occurrence in the 30 days following surgery, or pulmonary embolism or death. Investigators at more than 120 sites, worldwide, evaluated a liquid form of heparin, consisting of the Emisphere® carrier, SNAC (Sodium N-[8-(2 hydroxybenzoyl)amino] caprylate) in combination with unfractionated heparin, when dosed orally in a 30-day regimen, compared to Lovenox (enoxaparin), when dosed subcutaneously (by injection) in a 10-day regimen. The study design was double-blind and double-dummy. Total DVTs were determined by bilateral venogram, the FDA standard for measurement, measured at 30 days following surgery. All venographies produced were read by radiologists at Boston's Massachusetts General Hospital to determine the presence of a blood clot (thrombus).<< snip Cheers, Tuck